89bio, Inc.
89bio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 8, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 13, 2026.
10-Q for Q2 FY2025, filed Aug 8, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops pegozafermin, a drug candidate for patients with liver and cardio-metabolic diseases, including metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
10-K for FY2024, filed Feb 27, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 8, 2025
−$111.5MView ↗
- ▲ +132% (Loss)
- vs −$48M in Q2 FY2024
Compensated cirrhosis
The earlier report said the company was evaluating pegozafermin for patients with compensated cirrhosis; the latest describes an active dedicated trial for that group.
10-K for FY2021, filed Mar 24, 2022 10-K for FY2024, filed Feb 27, 2025We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the…View ↗
The Phase 3 program (ENLIGHTEN) is comprised of two Phase 3 trials evaluating pegozafermin in patients with MASH: (i) ENLIGHTEN-Fibrosis…View ↗
Who Did They Compete With?
Competes with Madrigal Pharmaceuticals, Novo Nordisk, Akero Therapeutics, Inventiva, Boehringer Ingelheim, Sagimet Biosciences, Boston Pharmaceuticals, Amarin, GlaxoSmithKline, Ionis, and Arrowhead Pharmaceuticals
10-K for FY2024, filed Feb 27, 2025If pegozafermin is approved for the treatment of MASH, future competition could also arise from select products that have been approved for…View ↗
Loading...
